RU2637645C1 - Method for indirect endolymphatic therapy in case of bronchopneumonia in dogs - Google Patents

Abstract

FIELD: veterinary medicine.

SUBSTANCE: invention concerns a method for treatment of dogs with bronchopneumonia characterized by appointment freshly prepared drug mixture in conjunction with conventional therapy by a complex of lymph-stimulating injections into the thickness of interspinous ligament of spine at the T10-T12 level; the mixture contains 32 U of Lydazum, 2 ml (6 mg) of Polyoxidonium®-vet, 4 ml of 5% novocaine solution and 4 ml of 40% glucose solution, in a dose of 1 ml per 1 kg of animal weight 5 times with an interval of 24 hours.

EFFECT: improved effectiveness of dogs therapy in case of bronchopneumonia by accelerating the seizure of inflammatory edema of respiratory organs, improving tissue oxygenation and accelerating the excretion of toxic products of inflammation by improving lymphovenous relationship in the respiratory region and stimulation of contractile and deposition ability of the ymphatic channel, increased overall immunological reactivity due to polyoxidonium introduction into the therapeutic scheme, shortened treatment.

1 ex, 1 tbl

Description

The invention relates to veterinary medicine and can be used in the complex treatment of dogs with bronchopneumonia of various etiologies, as well as complex therapy and prevention of pulmonary edema.

Respiratory diseases in dogs occupy a leading place in distribution and mass.

In the mechanism of development of bronchopneumonia, stagnation in the respiratory organs is of particular importance, leading to swelling of the mucous membranes of the bronchi and bronchioles, which significantly reduces the respiratory surface of the lungs and promotes the development of tissue hypoxia. In addition, with bronchopneumonia, the phagocytic activity of leukocytes and lysozyme activity of bronchial mucus are significantly reduced, and the barrier function of the epithelium is also reduced. Microorganisms that have absorbed into the blood and lymphatic channels, as well as their toxins and decay products, contribute to the development of endogenous intoxication, which is accompanied by a malfunction of various systems of the body of a sick animal.

The above facts necessitate the appointment of a comprehensive, pathogenetically substantiated treatment of dogs with bronchopneumonia.

Known methods for the complex treatment of dogs with bronchopneumonia, including oral, intramuscular or intravenous administration of broad-spectrum antimicrobial agents, correction of water-electrolyte balance, the appointment of expectorant drugs, bronchodilators, vitamin preparations and antioxidants, as well as preparations of interferon and its inducers [Arkadyev-Berlin N.G. Dog Treatment: A Veterinarian's Guide. Publisher: Veche, 2005; Vasilevich F.I. and others. Diseases of dogs. M .: Kolos, 2001.472 s .; Starchenkov S.V. Dog Disease St. Petersburg: Doe, 2001.560 s .; Nimand H.G., Suter P.B. Dog Disease A practical guide for veterinarians. 8th ed. / Per. with it., 2nd edition. M .: LLC "AQUARIUM PRINT", 2004. S. 391].

The disadvantages of these methods are the lack of pronounced enhancement of lymphatic drainage in the pathological focus, which makes it difficult to remove toxic products of inflammation and excess fluid from it, compressing the surrounding tissues and blood vessels.

The aim of the invention is to increase the effectiveness of therapy for bronchopneumonia in dogs by enhancing lymphatic drainage and eliminating the swelling of the respiratory organs, quickly cleansing the pathological focus from harmful decay products of tissues, microbes and their toxins, increasing immunological reactivity, as well as accelerating the recovery of animals.

The essence of the proposed method of therapy for bronchopneumonia of dogs is to prescribe a course of lymphostimulating injections in combination with traditional therapy, including the use of broad-spectrum antimicrobial agents, bronchodilators and mucolytics.

According to the invention, against the background of traditional therapy, including the administration of antimicrobial, mucolytic and bronchodilating drugs, lymph-stimulating injections are made into the thickness of the interspinous ligament of the spine at the T10-T12 level of a freshly prepared drug mixture (32 units of lidase, 2 ml (6 mg) of the preparation Polyoxidonium ^® -vet, 4 ml of a 5% solution of novocaine and 4 ml of a 40% glucose solution) in a dose of 1 ml per 1 kg of animal weight 5 times with an interval of 24 hours.

To identify the clinical effectiveness of the proposed method according to the principle of analogs were selected 10 outbred male dogs weighing from 9 to 12 kg at the age of 2 to 6 years with acute catarrhal bronchopneumonia. All animals were divided into 2 groups: control and experimental, 5 animals each.

The animals of the control groups were treated according to the generally accepted method, including: intramuscular administration of the antibiotic Baytril (2.5% solution of enrofloxacin) at a dose of 0.2 ml / kg with an interval of 24 hours; oral administration of a mucolytic of bromhexine at a dose of 0.2 mg / kg with an interval of 12 hours; oral administration of the bronchodilator aminophylline at a dose of 10 mg / kg with an interval of 8 hours.

Dogs of the experimental group were treated by the claimed method using lymphostimulating injections into the thickness of the interspinous ligament of the spine at the T10-T12 level of a freshly prepared drug mixture (32 U of lidase, 2 ml (6 mg) of Polyoxidonium ^® -vet, 4 ml of 5% novocaine solution and 4 ml of a 40% glucose solution) at a dose of 1 ml per 1 kg of animal weight 5 times with an interval of 24 hours.

Additionally, the dogs of the experimental group were prescribed traditional treatment similar to that in dogs of the control group (intramuscular administration of the Baytril antibiotic (2.5% solution of enrofloxacin) at a dose of 0.2 ml / kg with an interval of 24 hours; oral administration of mucolytic bromhexine at a dose of 0, 2 mg / kg with an interval of 12 hours; oral administration of the bronchodilator aminophylline at a dose of 10 mg / kg with an interval of 8 hours.

All animals of the experimental and control groups were clinically examined daily, and a general clinical blood test was performed before treatment, on the 3rd, 5th, 7th and 10th days.

The research results are shown in table 1.

When comparing the effectiveness of the use of the generally accepted method of treating dogs with bronchopneumonia, including intramuscular administration of an antibiotic, oral administration of a mucolytic and bronchodilator and the inventive method, which consists in combining lymphostimulating injections with conventional therapy, the following conclusions are made:

Already on the 3rd day of therapy, the claimed method noted a significant decrease in white blood cell count and a decrease in the erythrocyte sedimentation rate in the blood, a significant decrease in cough, wheezing during auscultation of the lungs, clinical improvement, normalization of body temperature and restoration of appetite in 4 out of 5 (80.0 %) dogs of the experimental group.

After 3 days of treatment in the generally accepted way, there were no significant improvements in laboratory blood parameters in dogs of the control group. Clinical improvement, decreased cough, wheezing intensity and restoration of appetite were observed in only 2 out of 5 dogs (40.0%).

After 5 days of therapy with the dogs of the experimental groups, the claimed method showed complete optimization of the clinical condition of all animals, manifested by good appetite and a vigorous state, the absence of cough and wheezing during auscultation, as well as the normalization of all laboratory blood parameters compared to the initial state.

After 5 days of treating dogs in the control groups in the generally accepted way, clinical improvement was noted, expressed as the absence of cough, restoration of appetite, as well as improvement in hematological parameters (decreased leukocytosis, decreased ESR) in only 3 out of 5 dogs (60.0%). In 2 dogs from the control group, mild wheezing and coughing, depression, loss of appetite, as well as hematological parameters indicating the presence of an inflammatory reaction persisted.

On the 7th and 10th day of therapy by the claimed method, the laboratory blood counts and the clinical condition of the dogs of the experimental group remained stable.

In the traditional method of therapy, complete optimization of the clinical condition and hematological parameters in all animals of the control group were noted only on the 10th day.

Therefore, the best results were obtained in the treatment of dogs with bronchopneumonia of the claimed method, which consists in combining a course of lymphostimulating injections with traditional therapy, including the appointment of antibiotics, bronchodilators and mucolytics.

Based on the data obtained, we can conclude that the claimed method of therapy for bronchopneumonia in dogs can improve efficiency and reduce the duration of treatment.

The method can be easily implemented in the veterinary practice of organizations specializing in the treatment of dogs.

Claims (1)

A method of treating dogs with bronchopneumonia characterized by the appointment in combination with traditional therapy of a complex of lymphostimulating injections into the thickness of the interspinous ligament of the spine at the T10-T12 level of a freshly prepared drug mixture containing 32 U of lidase, 2 ml (6 mg) of Polyoxidonium ^® -vet, 4 ml 5 % novocaine solution and 4 ml of a 40% glucose solution, at a dose of 1 ml per 1 kg of animal weight 5 times with an interval of 24 hours.